- LTS LOHMANN Therapie-Systeme AG has announced the acquisition of Renaissance Lakewood, LLC, a US-based CDMO specialising in nasal sprays and sterile dosage forms.
- The transaction, expected to close by the end of November 2025, will integrate Renaissance’s 500-strong workforce and facilities into LTS’s global operations network.
LTS LOHMANN Therapie-Systeme AG (LTS) has announced the acquisition of Renaissance Lakewood, LLC, a United States-based contract development and manufacturing organisation (CDMO) that specialises in nasal sprays and sterile dosage forms. The deal is expected to close before the end of November 2025, pending regulatory approval.
Based in Lakewood, New Jersey, Renaissance operates multiple manufacturing suites for unit-dose, bi-dose, and multi-dose nasal sprays, as well as small-volume parenteral fill-finish vials. The company’s laboratories also provide R&D formulation development and spray characterisation services, supporting customers from early-stage development through commercial launch.
The acquisition will see Renaissance’s facilities become part of LTS’s global operations network, which includes sites in Andernach, Germany; West Caldwell, New Jersey; St. Paul, Minnesota; and Netanya, Israel. Founded in 1979 and owned by RoundTable Healthcare Partners, Renaissance brings a workforce of around 500 employees and advanced infrastructure to the LTS portfolio.
According to LTS, the move represents a key milestone in its strategy to expand its capabilities in the CDMO space and to strengthen its position within the contract manufacturing community. By integrating Renaissance’s technologies and expertise, LTS aims to offer a broader range of drug delivery solutions to pharmaceutical and biotech partners.
“We are delighted to welcome Renaissance Lakewood to the LTS family. This acquisition marks a significant step in our strategy to expand our CDMO capabilities and strengthen our position as a global leader in innovative drug delivery solutions.”
Bas van Buijtenen, CEO of LTS
